{"id":"https://openalex.org/W4361883156","doi":"https://doi.org/10.1158/1078-0432.22451898","title":"Supplementary Tables 1 - 3 from Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study","display_name":"Supplementary Tables 1 - 3 from Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361883156","doi":"https://doi.org/10.1158/1078-0432.22451898"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22451898","doi":"https://doi.org/10.1158/1078-0432.22451898","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22451898","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.22451898","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039864062","display_name":"Amar J. Gajjar","orcid":"https://orcid.org/0000-0001-5019-0699","observed_orcids":["https://orcid.org/0000-0001-5019-0699"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amar Gajjar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043293908","display_name":"Clinton F. Stewart","orcid":"https://orcid.org/0000-0002-1546-9720","observed_orcids":["https://orcid.org/0000-0002-1546-9720"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Clinton F. Stewart","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071632296","display_name":"David W. Ellison","orcid":"https://orcid.org/0000-0003-1239-7757","observed_orcids":["https://orcid.org/0000-0003-1239-7757"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David W. Ellison","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112466226","display_name":"Sue Creviston Kaste","orcid":"https://orcid.org/0000-0003-4982-4118","observed_orcids":["https://orcid.org/0000-0003-4982-4118"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sue Kaste","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042463331","display_name":"Larry E. Kun","orcid":"https://orcid.org/0000-0003-0386-419X","observed_orcids":["https://orcid.org/0000-0003-0386-419X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Larry E. Kun","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025567999","display_name":"Roger J. Packer","orcid":"https://orcid.org/0000-0001-9413-7531","observed_orcids":["https://orcid.org/0000-0001-9413-7531"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roger J. Packer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071378074","display_name":"Stewart Goldman","orcid":"https://orcid.org/0000-0003-0134-1352","observed_orcids":["https://orcid.org/0000-0003-0134-1352"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stewart Goldman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083288793","display_name":"Murali Chintagumpala","orcid":"https://orcid.org/0000-0003-2686-6737","observed_orcids":["https://orcid.org/0000-0003-2686-6737"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Murali Chintagumpala","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Dana Wallace","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dana Wallace","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082874698","display_name":"Naoko Takebe","orcid":"https://orcid.org/0000-0002-5790-4954","observed_orcids":["https://orcid.org/0000-0002-5790-4954"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Naoko Takebe","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110213508","display_name":"James M. Boyett","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James M. Boyett","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083891481","display_name":"Richard J. Gilbertson","orcid":"https://orcid.org/0000-0001-7539-9472","observed_orcids":["https://orcid.org/0000-0001-7539-9472"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard J. Gilbertson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5006841058","display_name":"Tom Curran","orcid":"https://orcid.org/0000-0003-1444-7551","observed_orcids":["https://orcid.org/0000-0003-1444-7551"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tom Curran","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9878000020980835,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12009","display_name":"Hedgehog Signaling Pathway Studies","score":0.006300000008195639,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vismodegib","display_name":"vismodegib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/medulloblastoma","display_name":"medulloblastoma","score":0.9950000047683716},{"id":"https://openalex.org/keywords/pediatric-brain-tumors","display_name":"pediatric brain tumors","score":0.7850000262260437},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.9340000152587891},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.9929999709129333},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9919999837875366},{"id":"https://openalex.org/keywords/unbound-drug-concentration","display_name":"unbound drug concentration","score":0.800000011920929},{"id":"https://openalex.org/keywords/hedgehog-pathway-inhibitors","display_name":"Hedgehog pathway inhibitors","score":0.843999981880188}],"concepts":[{"id":"https://openalex.org/C2779545874","wikidata":"https://www.wikidata.org/wiki/Q2070286","display_name":"Vismodegib","level":4,"score":0.9833362102508545},{"id":"https://openalex.org/C2780789225","wikidata":"https://www.wikidata.org/wiki/Q1333608","display_name":"Medulloblastoma","level":2,"score":0.8850846290588379},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5697299242019653},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.47220975160598755},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4580494463443756},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.410391628742218},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3957764506340027},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.37835007905960083},{"id":"https://openalex.org/C2778804307","wikidata":"https://www.wikidata.org/wiki/Q809758","display_name":"Basal cell carcinoma","level":3,"score":0.15120753645896912},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.14463520050048828},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.07838204503059387},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C3019992690","wikidata":"https://www.wikidata.org/wiki/Q92767510","display_name":"Basal cell","level":2,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.22451898","doi":"https://doi.org/10.1158/1078-0432.22451898","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22451898","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.22451898.v1","doi":"https://doi.org/10.1158/1078-0432.22451898.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22451898.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Tables_1_-_3_from_Phase_I_Study_of_Vismodegib_in_Children_with_Recurrent_or_Refractory_Medulloblastoma_A_Pediatric_Brain_Tumor_Consortium_Study/22451898/1/files/39902976.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22451898","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Tables_1_-_3_from_Phase_I_Study_of_Vismodegib_in_Children_with_Recurrent_or_Refractory_Medulloblastoma_A_Pediatric_Brain_Tumor_Consortium_Study/22451898","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22451898","doi":"https://doi.org/10.1158/1078-0432.22451898","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22451898","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361883156.pdf","grobid_xml":"https://content.openalex.org/works/W4361883156.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2099469211","https://openalex.org/W4361951065","https://openalex.org/W2603489900","https://openalex.org/W2586065840","https://openalex.org/W3141379116","https://openalex.org/W4236143131","https://openalex.org/W7160852509","https://openalex.org/W2111433192","https://openalex.org/W2002969097","https://openalex.org/W2528184946"],"abstract_inverted_index":{"PDF":[0],"file":[1],"-":[2],"104K,":[3],"Supplementary":[4,10,20],"Table":[5,11,21],"S1.":[6],"Vismodegib":[7,26],"Dosing":[8],"Strategy":[9],"S2.":[12],"Commonly":[13],"Reported":[14],"Adverse":[15],"Events":[16],"According":[17],"to":[18],"Grade":[19],"S3.":[22],"Pharmacokinetics":[23],"of":[24],"Unbound":[25],"in":[27],"Pediatric":[28],"Patients":[29],"with":[30],"Medulloblastoma":[31]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}